Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma —...
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mandatory research projects during medical specialist training in Australia and New Zealand.

The Medical journal of Australia·2025
Same author

Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements.

BMJ (Clinical research ed.)·2025
Same author

Mandatory research projects during medical specialist training in Australia and New Zealand: a survey of trainees' experiences and reports.

The Medical journal of Australia·2025
Same author

Dopamine-mediated plasticity preserves excitatory connections to direct pathway striatal projection neurons and motor function in a mouse model of Parkinson's disease.

bioRxiv : the preprint server for biology·2024
Same author

Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?

Healthcare (Basel, Switzerland)·2022
Same author

Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study.

Drug safety·2022

相关实验视频

Updated: Jul 10, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

药物的差价定价:成本效益分析的作用?

Ruth Lopert1, Danielle L Lang, Suzanne R Hill

  • 1WHO Collaborating Centre for Training in Pharmacology and Rational Drug Use, School of Medical Practice and Population Health, Faculty of Health, University of Newcastle, New South Wales, Australia.

Lancet (London, England)
|June 28, 2002
PubMed
概括

高昂的药品成本阻碍了全球的治疗机会. 本研究提出了一种基于国家财富和成本效益的差异化药品价格设定方法,以帮助基本药品的国际价格谈判.

科学领域:

  • 卫生经济学 卫生经济学
  • 制药政策 制药政策
  • 全球健康 全球健康

背景情况:

  • 高昂的药品价格在全球范围内为获得基本治疗造成了重大障碍.
  • 药品成本因可负担性而异的差价概念已经确立,但缺乏明确的确定方法.
  • 由于与成本相关的问题,许多人仍然无法获得必需的药物.

研究的目的:

  • 为确定药品价格差异提出明确的方法.
  • 根据国家经济能力,使基本药品的价格差异化.
  • 为国际价格谈判提供一个框架.

主要方法:

  • 开发了一种方法,使用成本效益分析来推导药品指标价格.
  • 在成本效益计算中纳入了一种衡量国家财富的方法.
  • 作为一个案例研究,利用了血管激素转化酶抑制剂.

主要成果:

  • 展示了一种可量化的方法来计算药品价格差异.
  • 展示了国家财富如何融入定价模型.
  • 提供了一个使用特定药物类别的例子.

结论:

更多相关视频

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

相关实验视频

Last Updated: Jul 10, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

  • 拟议的方法为在国际上设定药品价格差异提供了基础.
  • 对国家财富进行调整后的成本效益分析可以指导价格谈判.
  • 这种方法可以改善全球获得基本药品的机会.